What is SterRx?
Operating as an FDA-registered 503B outsourcing facility, SterRx functions as a critical node in the pharmaceutical supply chain. Based in a 50,000-square-foot facility in Plattsburgh, New York, the company specializes in sterile drug manufacturing. By maintaining a workforce with extensive experience in cGMP environments, SterRx addresses the complex regulatory and technical requirements inherent in the production of sterile medications, positioning itself as a reliable partner for healthcare providers requiring high-quality, compliant pharmaceutical solutions.
How much funding has SterRx raised?
SterRx has raised a total of $15M across 1 funding round:
Private Equity
$15M
Private Equity (2017): $15M, investors not publicly disclosed
Key Investors in SterRx
SterRx
Undisclosed investor participating in the funding round.
What's next for SterRx?
With this major enterprise-level funding, SterRx is poised to accelerate its growth trajectory by optimizing its manufacturing throughput and expanding its market reach. The strategic allocation of this capital will likely focus on enhancing facility automation, deepening regulatory compliance infrastructure, and scaling production to meet the increasing demand for outsourced sterile drug manufacturing. As the company matures, its focus will remain on maintaining the stringent quality standards necessary to serve the broader healthcare sector, ensuring long-term viability in a highly regulated industry.
See full SterRx company page
